OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
Kang Wang, Yan‐Jun Xiang, Hongming Yu, et al.
Nature Medicine (2024) Vol. 30, Iss. 3, pp. 708-715
Closed Access | Times Cited: 52
Kang Wang, Yan‐Jun Xiang, Hongming Yu, et al.
Nature Medicine (2024) Vol. 30, Iss. 3, pp. 708-715
Closed Access | Times Cited: 52
Showing 1-25 of 52 citing articles:
Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives
Ke-Yu Shen, Ying Zhu, Sun‐Zhe Xie, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 41
Ke-Yu Shen, Ying Zhu, Sun‐Zhe Xie, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 41
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Bruno Sangro, Lorenza Rimassa, Maxime Ronot, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 23
Bruno Sangro, Lorenza Rimassa, Maxime Ronot, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 23
Liver diseases: epidemiology, causes, trends and predictions
Can Gan, Yuan Yuan, Haiyuan Shen, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 3
Can Gan, Yuan Yuan, Haiyuan Shen, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 3
Immunotherapy for hepatocellular carcinoma: The next evolution in expanding access to liver transplantation
Michael Li, Sherrie Bhoori, Neil Mehta, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 4, pp. 743-755
Closed Access | Times Cited: 16
Michael Li, Sherrie Bhoori, Neil Mehta, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 4, pp. 743-755
Closed Access | Times Cited: 16
Immunotherapy for hepatocellular carcinoma
Alexa Childs, Gloryanne Aidoo-Micah, Mala K. Maini, et al.
JHEP Reports (2024) Vol. 6, Iss. 10, pp. 101130-101130
Closed Access | Times Cited: 12
Alexa Childs, Gloryanne Aidoo-Micah, Mala K. Maini, et al.
JHEP Reports (2024) Vol. 6, Iss. 10, pp. 101130-101130
Closed Access | Times Cited: 12
Hepatocellular carcinoma: Revising the surgical approach in light of the concept of multiparametric therapeutic hierarchy
Umberto Cillo, Enrico Gringeri, F. D’Amico, et al.
Digestive and Liver Disease (2025)
Closed Access | Times Cited: 1
Umberto Cillo, Enrico Gringeri, F. D’Amico, et al.
Digestive and Liver Disease (2025)
Closed Access | Times Cited: 1
Advancements in immunotherapy for hepatocellular carcinoma
S. Ascari, Rusi Chen, Caterina Vivaldi, et al.
Expert Review of Anticancer Therapy (2025) Vol. 25, Iss. 2, pp. 151-165
Closed Access | Times Cited: 1
S. Ascari, Rusi Chen, Caterina Vivaldi, et al.
Expert Review of Anticancer Therapy (2025) Vol. 25, Iss. 2, pp. 151-165
Closed Access | Times Cited: 1
Precision surgery for hepatocellular carcinoma
Christian Tibor Josef Magyar, Luckshi Rajendran, Zhihao Li, et al.
The Lancet. Gastroenterology & hepatology (2025)
Closed Access | Times Cited: 1
Christian Tibor Josef Magyar, Luckshi Rajendran, Zhihao Li, et al.
The Lancet. Gastroenterology & hepatology (2025)
Closed Access | Times Cited: 1
Immunotherapy at all stages of hepatocellular carcinoma
David J. Pinato, Claudia Angela Maria Fulgenzi, Antonio D’Alessio
Nature Medicine (2024) Vol. 30, Iss. 3, pp. 640-641
Closed Access | Times Cited: 8
David J. Pinato, Claudia Angela Maria Fulgenzi, Antonio D’Alessio
Nature Medicine (2024) Vol. 30, Iss. 3, pp. 640-641
Closed Access | Times Cited: 8
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis
Antonio D’Alessio, Bernardo Stefanini, Julia Blanter, et al.
The Lancet Oncology (2024)
Open Access | Times Cited: 6
Antonio D’Alessio, Bernardo Stefanini, Julia Blanter, et al.
The Lancet Oncology (2024)
Open Access | Times Cited: 6
Gold Nano Frameworks with Mesopores for Synergistic Immune-Thermal Therapy in Hepatic Carcinoma: A Paradigm Shift in Immune Checkpoint Blockade
Lei Feng, Bin Luo, Bei Li, et al.
ACS Applied Materials & Interfaces (2024) Vol. 16, Iss. 35, pp. 45901-45916
Closed Access | Times Cited: 4
Lei Feng, Bin Luo, Bei Li, et al.
ACS Applied Materials & Interfaces (2024) Vol. 16, Iss. 35, pp. 45901-45916
Closed Access | Times Cited: 4
Perioperative Tislelizumab plus intensity modulated radiotherapy in resectable hepatocellular carcinoma with macrovascular invasion: a phase II trial
Hongyu Pan, Liuyu Zhou, Zhuo Cheng, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Hongyu Pan, Liuyu Zhou, Zhuo Cheng, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
The tumor distance to the main hepatic vessels is a predictor of recurrence-free survival and overall survival in hepatocellular cancer
Schaima Abdelhadi, Johann S. Rink, Matthias F. Froelich, et al.
Langenbeck s Archives of Surgery (2025) Vol. 410, Iss. 1
Open Access
Schaima Abdelhadi, Johann S. Rink, Matthias F. Froelich, et al.
Langenbeck s Archives of Surgery (2025) Vol. 410, Iss. 1
Open Access
Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial
Tao Ma, Xueli Bai, Qi Zhang, et al.
Hepatology (2025)
Closed Access
Tao Ma, Xueli Bai, Qi Zhang, et al.
Hepatology (2025)
Closed Access
Cirrhosis and complications hepatocellular carcinoma – expanding indications for immunotherapy
Helena Degroote
Acta Clinica Belgica (2025), pp. 1-7
Closed Access
Helena Degroote
Acta Clinica Belgica (2025), pp. 1-7
Closed Access
Structural insights into antibody-based immunotherapy for hepatocellular carcinoma
Masaud Shah, Muhammad Hussain, Hyun Goo Woo
Genomics & Informatics (2025) Vol. 23, Iss. 1
Open Access
Masaud Shah, Muhammad Hussain, Hyun Goo Woo
Genomics & Informatics (2025) Vol. 23, Iss. 1
Open Access
Juglone induces ferroptotic effect on hepatocellular carcinoma and pan-cancer via the FOSL1-HMOX1 axis
Chuyu Wang, Ying Zhao, Yingfei Peng, et al.
Phytomedicine (2025), pp. 156417-156417
Closed Access
Chuyu Wang, Ying Zhao, Yingfei Peng, et al.
Phytomedicine (2025), pp. 156417-156417
Closed Access
Meta-analysis of the efficiency and safety of neoadjuvant therapy with immune checkpoint inhibitors in resectable hepatocellular carcinoma
Adili Tuersun, Yadikaer Yasen, Munire Mohetaer, et al.
Frontiers in Medicine (2025) Vol. 11
Open Access
Adili Tuersun, Yadikaer Yasen, Munire Mohetaer, et al.
Frontiers in Medicine (2025) Vol. 11
Open Access
Systemic therapy for hepatocellular carcinoma, from the early to the advanced stage: a Japanese perspective
Masafumi Ikeda, Chigusa Morizane, Makoto Ueno, et al.
Japanese Journal of Clinical Oncology (2025)
Open Access
Masafumi Ikeda, Chigusa Morizane, Makoto Ueno, et al.
Japanese Journal of Clinical Oncology (2025)
Open Access
Where Is the Future of Adjuvant Therapy for Hepatocellular Carcinoma?
Yizhen Fu, Yaojun Zhang, Dandan Hu, et al.
Journal of Clinical Oncology (2025)
Closed Access
Yizhen Fu, Yaojun Zhang, Dandan Hu, et al.
Journal of Clinical Oncology (2025)
Closed Access
Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review
Edoardogregorio Galli, Giorgio Patelli, Federica Villa, et al.
Cancer Treatment Reviews (2025) Vol. 135, pp. 102908-102908
Open Access
Edoardogregorio Galli, Giorgio Patelli, Federica Villa, et al.
Cancer Treatment Reviews (2025) Vol. 135, pp. 102908-102908
Open Access
Letter: Comparing the Efficacy of Adjuvant PD –1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologies—Authors' Reply
Isabella Lurje, Deniz Uluk, Frank Tacke, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access
Isabella Lurje, Deniz Uluk, Frank Tacke, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access
Comprehensive insights into systemic therapy for the whole-course management of hepatocellular carcinoma
Jiayun Jiang, Kai Feng, Leida Zhang, et al.
Oncology and Translational Medicine (2025)
Open Access
Jiayun Jiang, Kai Feng, Leida Zhang, et al.
Oncology and Translational Medicine (2025)
Open Access
Liver resection for hepatocellular carcinoma with vascular invasion: Current insights and future perspectives
Tong Yuan, Junjie Liu, Xing Lv, et al.
Oncology and Translational Medicine (2025)
Open Access
Tong Yuan, Junjie Liu, Xing Lv, et al.
Oncology and Translational Medicine (2025)
Open Access
Immune therapies in intermediate-advanced unresectable hepatocellular carcinoma: Changing the therapeutic landscape
Sagnik Biswas, Arghya Samanta
World Journal of Gastroenterology (2025) Vol. 31, Iss. 14
Closed Access
Sagnik Biswas, Arghya Samanta
World Journal of Gastroenterology (2025) Vol. 31, Iss. 14
Closed Access
